Blood lead levels and multiple sclerosis: A case-control study.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 05 04 2018
revised: 09 08 2018
accepted: 13 10 2018
pubmed: 2 11 2018
medline: 17 4 2019
entrez: 2 11 2018
Statut: ppublish

Résumé

Multiple sclerosis (MS) is a debilitating disease of the central nervous system, with disseminating demyelination of nerve fibers and spinal cord. Exposure to heavy metals seems to be associated with a higher incidence of MS. Few studies have assessed the correlation of the incidence of MS with heavy metal concentrations. The present study aimed to assess the relationship between blood lead levels and MS. This case-control study was conducted on 29 MS patients and 29 healthy control persons. The controls were age, gender and occupation matched at the time of blood sampling. Blood lead levels were measured using the atomic absorption spectrometry method. Data were analyzed using Student t-test, Mann-Whitney U, and multiple logistic regression, using a significance level of p ˂ 0.05. According to the result of this study, the mean blood lead level (BLL) was 75.6 ± 9.35and33.8 ± 28.8 µg/L in patients with MS and control group, respectively. Median blood lead levels were significantly higher in MS patients (38 µg/L, range: 27-67), compared to the controls (30 µg/L, range: 11-49) (p = 0.03). The risk of MS increased 1.17 times per one µg/L increment of blood lead level, using the multiple logistic regression analysis on the present results. In conclusion, based on our results, BLL was higher in MS patients, compared with healthy individuals. The risk of MS increased 1.17 times per one µg/L increment of blood lead level.

Sections du résumé

BACKGROUND BACKGROUND
Multiple sclerosis (MS) is a debilitating disease of the central nervous system, with disseminating demyelination of nerve fibers and spinal cord. Exposure to heavy metals seems to be associated with a higher incidence of MS. Few studies have assessed the correlation of the incidence of MS with heavy metal concentrations. The present study aimed to assess the relationship between blood lead levels and MS.
METHODS METHODS
This case-control study was conducted on 29 MS patients and 29 healthy control persons. The controls were age, gender and occupation matched at the time of blood sampling. Blood lead levels were measured using the atomic absorption spectrometry method. Data were analyzed using Student t-test, Mann-Whitney U, and multiple logistic regression, using a significance level of p ˂ 0.05.
RESULTS RESULTS
According to the result of this study, the mean blood lead level (BLL) was 75.6 ± 9.35and33.8 ± 28.8 µg/L in patients with MS and control group, respectively. Median blood lead levels were significantly higher in MS patients (38 µg/L, range: 27-67), compared to the controls (30 µg/L, range: 11-49) (p = 0.03). The risk of MS increased 1.17 times per one µg/L increment of blood lead level, using the multiple logistic regression analysis on the present results.
CONCLUSION CONCLUSIONS
In conclusion, based on our results, BLL was higher in MS patients, compared with healthy individuals. The risk of MS increased 1.17 times per one µg/L increment of blood lead level.

Identifiants

pubmed: 30384201
pii: S2211-0348(18)30372-9
doi: 10.1016/j.msard.2018.10.010
pii:
doi:

Substances chimiques

Lead 2P299V784P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-155

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Mohammad Dehghanifiroozabadi (M)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Moallem Avenue, Birjand, Iran.

Parisa Noferesti (P)

Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.

Alireza Amirabadizadeh (A)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Moallem Avenue, Birjand, Iran.

Samaneh Nakhaee (S)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Moallem Avenue, Birjand, Iran.

Jan Aaseth (J)

Inland Norway University of Applied Sciences, Elverum, and Research Department, Innlandet Hospital, Brumunddal, Norway.

Farshid Noorbakhsh (F)

Department of Immunology, Tehran University of Medical Sciences, Iran.

Omid Mehrpour (O)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Moallem Avenue, Birjand, Iran; Rocky Mountain Poison and Drug Center, Denver, CO, USA. Electronic address: omid.mehrpour@rmpdc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH